title: Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial.
abstract: OBJECTIVE
  To evaluate topiramate (TPM) and phenytoin (PHT) monotherapy following rapid oral initiation in new-onset epilepsy.
  
  
  METHODS
  Randomized, double-blind, 28-day trial of TPM (100 mg/day beginning on day 1) versus PHT (1,000 mg on day 1 followed by 300 mg/day maintenance dosing) in 261 patients with new-onset epilepsy. The primary end point was time to seizure, and the primary objective was to establish noninferiority of TPM to PHT in the risk of seizure.
  
  
  RESULTS
  At day 28, the estimated seizure-free rate was 81.1% for TPM treatment in comparison with 90.3% for PHT treatment. Noninferiority of TPM to PHT (primary objective) could not be established [hazard ratio (HR) 2.0, 95% confidence interval (CI), 0.98 to 4.12, p = 0.366), and PHT could not be shown to be superior to TPM. A higher percentage discontinued with PHT compared to TPM for all reasons (21.1 vs. 12.8%) and due to adverse events (13.4 vs. 6.8%). The most common treatment-related adverse events in both groups were dizziness, paresthesia, and somnolence. A post hoc analysis showed that TPM was superior to PHT in time to discontinuation (retention rate) for all causes (89.4% vs. 80.3%, p = 0.047).
  
  
  CONCLUSIONS
  This study was inconclusive in establishing noninferiority of TPM 100 mg/day compared to a standard regimen of oral PHT in seizure risk in this population of patients with new-onset epilepsy. Given the superiority of TPM in overall retention and favorable tolerability without titration, it may nonetheless be an appropriate option in some patients with new-onset epilepsy requiring rapid treatment initiation.
authors.affiliation: Epilepsy Institute, Ochsner Baptist Medical Center, New Orleans, Louisiana 70115, USA. eramsay@epiworld.com
authors.forename: Eugene
authors.initials: E
authors.lastname: Ramsay
authors.forename: Edward
authors.initials: E
authors.lastname: Faught
authors.forename: Allan
authors.initials: A
authors.lastname: Krumholz
authors.forename: Dean
authors.initials: D
authors.lastname: Naritoku
authors.forename: Michael
authors.initials: M
authors.lastname: Privitera
authors.forename: Lesley
authors.initials: L
authors.lastname: Schwarzman
authors.forename: Lian
authors.initials: L
authors.lastname: Mao
authors.forename: Frank
authors.initials: F
authors.lastname: Wiegand
authors.forename: Joseph
authors.initials: J
authors.lastname: Hulihan
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D064420:Drug-Related Side Effects and Adverse Reactions; D004632:Emergency Medical Services / Q000379:methods; D004827:Epilepsy / Q000188:drug therapy* / Q000517:prevention & control; D005260:Female; D005632:Fructose / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010672:Phenytoin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D012307:Risk Factors; D000077236:Topiramate; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose; D010672:Phenytoin